UBS therefore closed out the quarter with $6.7 million shares.
My guess is that UBS has clearly done thier due diligence and bought significantly more PSEC last quarter, after already accumulating a nice position in prior quarters/years.
Of course a sharp rise in interest rates could possibly result in credit defaults by Prospect's customers, but modestly riising interest rates could be the best scenario for Prospect shareholders increasing the spreads between Prospest fixed borrowings and their floating rate loans to customers.
My guess is that UBS is betting interest rate increases will be modest and Prospect will prosper as a result.
Best wishes to all Prospect shareholders.
Sometimes funds have a way of resting a while before transfer. Please advise if you have received your funds and which brokerage company.
Presume the funds transfer will be automatic, without the need for shareholder requests.
Best wishes to all,
Clearly, Corgenix is more valuable as a Corporate entity with the WHO and FDA approvals on the rapid Ebola test. Unfortunately, all of this happened quickly, but after the company was shopped around.
Considering that many companies may have previously considered CONX as a possible acquisition, and considerring the possible benefits of keeping this technology in the US as a matter of national security interest, it would seem that another US company would now consider CONX in this new light, and consider any exit penalties as part of the acquisition costs.
If we beliieve in the percentage of VTSS design wins, and the expected production runs from those design wins ... combined with the worldwide explosion of data and video traffic, then eventually investors will turn their attention from the software providers to the infrastructure providers... and particularly those who are adept at secure transmissions.
That's my vision and I am sticking to it.
"We are the only provider of 1G, 10GE PHY that combine encryption plus accurate 5088 packet timing, so we are well-positioned for the surge with secured networking."
Given the huge public attention on security issues, I can't imagine selling VTSS while Vitesse is ramping up on its latest design wins.
Remember 1999 and 2000 when investors focused more on internet infrstructure than on social networking??
Imagine if VTSS goes back to even a quarter of its former highs.
Sentiment: Strong Buy
The above subject was from today's (2/4/15) Wall Street Journal, page A15. The article was written by Peter Gruber and Paul Howard of the Manhattan Institute and can be pulled up on the Manhattan Institute website.
This article could have well described the plight of BSD Medical's BSD 2000 and the huge toll it has taken financially on BSD Medical trying to gain approval for deep tissue hyperthermia for multiple cancer applications.
How can we, as a nation, have allowed these regulations to stifel medical device advancements from start up companies or microcap companies, particularly when the cancer treatment benefits are significant and the treatments are non invasive?
There are names of 4 Congressmen and women in the article, two of which head up 21st Century Cures Initiative. Call them, tell them how you feel.
I cannot fathom why a non invasive deep tissue cancer treatment was limited in its FDA approval to cervical cancer, thereby dramatically limiting its chances of capital purchase by hospitals for one cancer application only and serving as just cause to deny insurance coverage for all other deep tissue hyperthermia cancer applications.
As a shareholder and citizen of the US, I am outraged that these regulatory decisions are so critical that doctors and patients do not have the choice for hyperthermia, even if the patient is dying from the disease, for example pancreatic cancer.
I can only hope that BSD Medical has tried both congressional and public appeals to advance its efforts for deep tissue hyperthermia.
Certainly, a similar article in the WSJ by the Manhattan Institute would have drawn a huge audience to the plight of this small microcap (BSDM) to break down the barriers in the US to make deep tissue hyperthermia available to all.
Wow, maybe it is time for you to go back to school Mr. buyer/seller.
The Cisco projections on telecom/internet are in direct contradiction to your statements. Of course you must be the authority, not Cisco. Maybe you still think of telecom as confined to the wireline space.
API's HSOR's for 100G are leading edge products for a communications world that is grapping with a 20 fold surge in video demand, both wireline and wireless.
The reason you "can't think of anything positive to say" is because you enjoy the thrill of trashing microcap stocks, all the while claiming to be a shareholder. Smart indeed.
You and littlemoney have a lot in common.
Amazing that much talent in two posters who clearly are smart enough to find a stock they like and yet spend their days trashing stocks of microcap companies.
Luna and API both presented credible reasons for merging both from a product line basis, customer basis, and from a reduction in overhead from the combination of public companies.
Buyer/Seller, if you think that merger synergies is an accounting only based savings, you need to go back to your basic accounting 101 book and try to remember the various aspects of overhead for each company as a public entity.
Buyer/seller, congratulations, your lack of civility and second grade name calling earn you the ignore button.
Thank you bigmoney for that hearty endorsment.
For one, I was not run out of the API board but rather chose to stop reading and responding to the negative drivel from API posters such as yourself. Not regrettably, I have passed up reading all of your Investor Village posts with the ignore buttom. Glad you find reading my posts so worthwhile.
Unlike yourself, I realized that API chose to sacrifice profits for the design and production of world class products, with the latest announcement of the hand held terahertz scanner.
The next step for API, with limited cash resouces, was to find a company to merge with or partner with, in order to harvest these technologial advances.
Unlike yourself, Luna has evaluated the API company products and has chosen to invest in these complimentary products and to mutually benefit from the reduction of the costs required to be a small microcap public company.
Bigmoney, please spare this board your negativity and find a stock you like.
Regards to all API and Luna shareholders,
Thank you babe ... wish I was right "always", but with microcaps, I am happy to get just a few right.
Unfortunately, LUNA shareholders do not currently appreciate (for the moment) the technology they are gaining in both HSOR & terahertz for a small fraction of the cost to develop these technologies.
My guess is that some institutions who understand both companies and both intellectual properties will begin to accumulate shares of either company or both.
You might want to read my post again. Did you happen to read the parts about the API technology ... or about the overall reductions in overhead when two small public companies merge.
Good try on the slam however. .
Apologize for the typos in my previous message :-)
Anyways, I negelected to encourage you as LUNA shareholders to also study the API high speed optical receivers targeted for 100G and consider how 100G is very early in its roll out as the internet grapples with exploding demand for bandwidth, particularly for video.
As a long time shareholder of API, I have been impressed by their own technology both in high speed optical receivers and terahertz. What has been difficult is the difficulty to make a bottom line profit with all the requirements and overhead of a small public company.
Now there will be one Board of Directions, one Auditor, one set of financials, one annual report, one headquarters, one human sources director, etc, etc.
The cost savings for the combined companies should be enormous.
I like what I see with Luna and will remain a shareholder after the merger.
Luna shareholders need to dig deep re. API before selling now. IMO, this is a brilliant move to acquire incredible API technology for a modest price. Study the handheld terahertz scanner and imagine the applications worldwide.
As an API shareholder, I will likewise dig deep into your products, but so far I know that you have leading edge products, in the same fashion of API.
Blessings to all,
First of all, this was a nice day indeed to see a significant percentage increase (60%) in the stock price on very heavy volume. I hope this is the start of a long term uptrend to help make your long term stakeholders whole.
In terms of Binder's post on the IV board, I trust that the BSDM board of directors is doing their due diligence in not only hiring an investment banker with worldwide contacts in the medical space, but also that BSD Medical will provide evidence to shareholders detailing such worldwide efforts before the completion of the hyperthermia product line sale. This certainly could be handled in an investor conference call or press release with modest expense to the company.
Ironically, Corgenix (CONX... a small cap medical diagnostic co.) has recently done a stellar job of marketing the entire company, yet by not disclosing in advance the extensive detailed marketing efforts, some disgruntled CONX shareholders delayed the entire takeover process by appx. four to five months to obtain the details, at significant legal expense to Corgenix. BTW, I was not part of that disgruntled CONX investor group.
I know that I don't speak for all BSDM shareholders, but I do understand the enormity of the job to move this company forward, to grow its top and bottom lines, and to advance cancer and ablation treatments worldwide. Welcome aboard Mr. Carnell. We wish you success in your endeavors.
My hope is that this company will prosper for the sake of those patients you serve and that prosperity will follow.
I presume you remain as a long term shareholder. This goes well beyond Easter Bunnies and for many cancer victims, it is a matter of life and death.
What can you do to make a difference??
Just as a point of clarification, I should have stated record hyperthermia pipelines as a result of multiple minimum order requirements from international distributions agreements.
The technology of hyperthermia has taken decades to develop all the technology, engineering, manufacturing techniques, vendor sourcing, FDA approvals, international approvals and distribution agreements, current backlog etc. This technology is material!! Just ask any cancer victim who has survived because of the dramatic hyperthermia benefits when used as a combined modality with either radiation or hyperthermia.
No doubt BSD Medical management has been frustrated at the huge regulatory burdens both domestic and international and the enormous economic hurdles.
The time is now to involve government officials with BSD Medical as a company struggling financially with hyperthermia products that can save lives when all hope seems lost. Let's cut through this regulatory maize and get it done. Let's get some press going through the Wall Street Journal. (Remember the articles in the WSJ re. delayed regulatory approvals on the heart valve replacement devices and the melanoma detection devices approved in Europe and not the US... and remember how soon thereafter the U.S. approvals followed.)
The time is now to find believers in BSD Medical and its hyperthermia technology who are willing to make sinificant grants and/or private investments in this company. I can think of several names of billionaires who are very motivated to help mankind. Don't scoff, the Gates Foundation just made a grant to another microcap medical stock I own for the good of mankind. Hats off to Mr. & Mrs Gates!!
I bought heavily into BSD Medical because of hyperthermia and cannot imagine any scenario that warrants "exiting" the business unless it is sold for its true value to a company that has the medical infrastructure to make hyperthermia a blessing to mankind.
The time is now, let's get to work to save this valuable hyperthermia technology. I am contacting my US Senator today. Do any of you know Mr. Huntsman, Mr. or Mrs. Gates or other philanthropic organizations?? Let's get to work now!!
No doubt every shareholder who bought BSD Medical shares believed in this hyperthermia technology, believed that regulatory hurdles could be addressed and challenged domestically and internationally, believed in the cancer treatment centers and hospitals that have already purchased the hyperthermia equipment, believed in the recent record international order backlogs for hyperthermia equipment, and believed in the blessings to come from those suffering with recurrent cancers.
Now BSD Medical has stated their intentions to exit the hyperthermia business in 2015 and does not expect a material benefit from the proceeds of such a possible sale.
BSD Medical plans to exit the hyperthermia business in which it has the leading worldwide technology, after investing tens of millions of dollars with the highest hyperthermia backlog in its history ... yet shareholders have been led to believe its market value may not material??
BSD Medical plans to exit the hyperthermia business in which it dominates worldwide, and then pour its remaining resources into the microwave ablation business that has struggled for several years to gain traction, has enormous competiton in both RF and microwave ablation... all with rapidly eroding cash reserves and potentially no attractive alternatives to raise more cash, excepting further shareholder dilution or debt with excessive rates and security requirements.
Certainly, from a humanitarian vantage point, the sale of the hyperthermia business and technology to a large US based company for $40 to $50 million would indeed be material to BSD Medical and would be reason to expect that the buyer would agressively make this hyperthermia technology available to desparate cancer victims worldwide.
(Continue to next post... part 2)
Bankruptcy usually takes debt ... which has not yet happened.
However, further shareholder dilution can be almost as painful.
I have remained on the sidelines as far as posting ... but the time is now!!